

Supplementary Table 1: Combined analysis of SNPs selected for validation of an association with more aggressive prostate cancer

SNP	Chr	Gene	Controls (N=1267)	OR	More Aggressive** (N=729)	
			MAF [†]		95% CI	<i>p</i> ^{††}
rs3774315	3q26	<i>TNFSF10</i>	0.25	1.22	1.05 - 1.41	4.3 x10 ⁻³
rs8015211	14q22	<i>FBXO34</i>	0.33	1.23	1.07 - 1.41	1.5 x10 ⁻³
rs12433615	14q22		0.31	1.23	1.07 - 1.41	1.5 x10 ⁻³
rs1188069	14q22		0.20	1.22	1.04 - 1.43	6.4 x10 ⁻³
rs2341883	14q22		0.32	1.29	1.12 - 1.48	1.5 x10 ⁻⁴
rs6497287	15q13	<i>HERC2</i>	0.06	1.56	1.20 - 2.01	4.0 x10 ⁻⁴
rs11150069	16q23	<i>WWOX</i>	0.30	0.88	0.76 - 1.02	4.0 x10 ⁻²
rs4628973	16q24		0.30	0.86	0.74 - 0.99	1.9 x10 ⁻²
rs225061	Xp21	<i>IL1RAPL1</i>	0.22	0.79	0.62 - 0.99	2.2 x10 ⁻²

[†]Minor Allele Frequency; [§]Two-sided p-value; ^{††}One-sided p-value; ^{**}All aggressive cases from the GWAS and replication stages.